Biomerica earnings for the first quarter of fiscal 2027 showed a roughly $1.2 million net loss as lower sales and a sharp decline in gross margin outweighed cost reductions. The diagnostic-products company reported the results on October 16, 2026, alongside early growth in Medicare-related orders for its inFoods IBS test after the August 31 quarter-end.
Key Takeaways
- Gross margin fell to 8% from 31%, outweighing a roughly 14% reduction in operating expenses.
- September Medicare-related orders rose 120% to 22; processed initial valid claims had been paid at $300 each.
- An August share placement lifted cash, while the board continued evaluating partnerships and business combinations.
Table of Contents
- Biomerica earnings reflect weaker sales and margins
- Medicare orders grow from an early-stage base
- Share placement strengthens cash position
- Development work and strategic review remain ongoing
- Conclusion
Biomerica earnings reflect weaker sales and margins
Biomerica’s fiscal 2027 first-quarter results showed net sales of approximately $1.3 million, down from $1.4 million a year earlier. The company attributed the decline mainly to fluctuations in clinical laboratory orders and shipment timing, partly offset by stronger over-the-counter sales and contract manufacturing revenue.
Gross profit dropped to approximately $103,000 from $424,000. Biomerica cited product mix, lower sales volume and the timing of manufacturing costs included in cost of sales. The resulting 23-percentage-point decline in gross margin left less profit available to cover operating costs.
Operating expenses fell to approximately $1.3 million from $1.5 million, reflecting lower administrative and personnel-related costs, including professional service fees. Even so, operating loss widened to about $1.2 million from $1.1 million.
Net loss was approximately $0.37 per share. The prior-year quarter’s roughly $2,000 net profit included approximately $1.1 million in Employee Retention Credit income, making that comparison materially different from the underlying operating-loss comparison.
| Item | Details |
|---|---|
| Over-the-counter sales | Approximately $291,000 in fiscal Q1 2027, up 81% year over year, primarily from a new customer. |
| Middle East sales | Increased approximately 59% from the prior-year quarter. |
| Working capital | Approximately $2.6 million at August 31, 2026, versus $1.5 million at May 31. |
| hp+detect distribution | Continued reorders from a major European clinical laboratory chain for the United Kingdom market. |
Medicare orders grow from an early-stage base
After quarter-end, Medicare-related inFoods IBS orders increased to 22 in September from 10 in August. That represented 120% growth, but the absolute volume remained small.
As of October 15, 32 customer locations were set up for Medicare ordering, compared with 25 at August 31. Thirteen locations had placed Medicare-related orders, including nine with repeat orders. The distinction matters: locations enabled to order had not all become active users.
Biomerica said all initial valid Medicare claims processed as of October 15 had been paid at the full $300 rate under the Clinical Laboratory Fee Schedule. Claims were still being considered individually, so the payment record should not be read as a guarantee that every future claim will be paid.
Share placement strengthens cash position
Cash and cash equivalents rose to approximately $2.7 million at August 31 from $1.3 million at May 31, primarily because of an August private placement. The financing raised approximately $2.23 million in gross proceeds through the sale of about 1.39 million common shares at $1.60 each, without warrants or discounted securities.
Operating activities used approximately $802,000 in cash, compared with $268,000 a year earlier. The earlier period included approximately $1.1 million in Employee Retention Credit cash receipts. Excluding those receipts, Biomerica said operating cash outflow was approximately 41% lower year over year.
Development work and strategic review remain ongoing
Biomerica continued development work for a confidential life sciences customer under an agreement with initial target fees exceeding $1.75 million. That amount is subject to additional statements of work, rather than being fully secured revenue. Payments depend on contractual milestones, while revenue is recognized as services are performed.
The company also engaged B. Riley Securities as exclusive financial adviser for the board’s evaluation of potential partnerships and business combinations. No transaction was announced, and Biomerica cautioned that the review might not produce one.
Conclusion
Biomerica’s cost reductions did not offset the quarter’s lower gross profit, while the share placement increased available cash. The ongoing commercialization effort, milestone-based development work and strategic review are the next areas to watch; the company announced no transaction or completion date for the review.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
